Skye Bioscience Inc (SKYE) reports significant advancements in clinical trials and financial stability, despite increased ...

Q2 2025 Management View Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Given this risk, we thought we'd take a look at whether Skye Bioscience (NASDAQ:SKYE) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate ...

Spruce Biosciences (SPRB) announces a 1-for-75 reverse stock split effective Aug 4, 2025, to meet Nasdaq requirements.

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need.

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

View the latest Skye Bioscience Inc. (SKYE) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Celldex Therapeutics has been a tenant at 300 George Street for some 10 years, but the space is now needed by landlord Yale.